Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000 2011.
The effect of recombinant factor VIII (rFVIII) brand on inhibitor development was investigated in all 407 severe hemophilia A previously untreated patients born in the United Kingdom (UK) between 1 January 2000 and 31 December 2011. Eighty eight (22% had been in the RODIN study. Information was extracted from the National Haemophilia Database. Because exposure days (EDs) were not known for some patients, time from first treatment was used as a surrogate for rFVIII exposure. An inhibitor developed in 118 (29% patients, 60 high and 58 low titer, after a median (interquartile range) of 7.8 (3.3 13.5) months from first exposure and 16 (9 30) EDs. Of 128 patients treated with Kogenate Bayer/Helixate NexGen, 45 (35.2% 95% confidence interval [CI] 27.4 43.8) developed an inhibitor compared with 42/172 (24.4% 95% CI 18.6% to 31.4% with Advate (P .04) The adjusted hazard ratio (HR) (95% CI) for Kogenate Bayer/Helixate NexGen compared with Advate was 2.14 (1.12 4.10) (P .02) for high titer and 1.75 (1.11 2.76) (P .02) for all inhibitors. When excluding UK RODIN patients, the adjusted HR (95% CI) for high titer inhibitors was 2.00 (0.93 4.34) (P .08) ReFacto AF was associated with a higher incidence of all, but not high titer, inhibitors than Advate. These results will help inform debate around the relative immunogenicity and use of rFVIII brands.
Blood